FAS Wealth Partners Inc. Increases Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

FAS Wealth Partners Inc. increased its holdings in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 47.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 139,535 shares of the company's stock after acquiring an additional 44,830 shares during the quarter. FAS Wealth Partners Inc. owned approximately 0.14% of ARS Pharmaceuticals worth $1,755,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of SPRY. Alliancebernstein L.P. lifted its stake in shares of ARS Pharmaceuticals by 5,168.4% during the 4th quarter. Alliancebernstein L.P. now owns 3,880,734 shares of the company's stock valued at $40,942,000 after buying an additional 3,807,074 shares in the last quarter. Vanguard Group Inc. grew its position in ARS Pharmaceuticals by 3.5% during the fourth quarter. Vanguard Group Inc. now owns 3,464,952 shares of the company's stock worth $36,555,000 after buying an additional 115,656 shares in the last quarter. Alyeska Investment Group L.P. raised its holdings in shares of ARS Pharmaceuticals by 903.0% in the 4th quarter. Alyeska Investment Group L.P. now owns 1,253,724 shares of the company's stock valued at $13,227,000 after acquiring an additional 1,128,724 shares in the last quarter. Geode Capital Management LLC raised its stake in ARS Pharmaceuticals by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 1,238,156 shares of the company's stock valued at $13,066,000 after purchasing an additional 3,351 shares in the last quarter. Finally, Woodline Partners LP increased its holdings in shares of ARS Pharmaceuticals by 13.5% in the 4th quarter. Woodline Partners LP now owns 1,119,283 shares of the company's stock worth $11,808,000 after buying an additional 133,276 shares during the last quarter. Hedge funds and other institutional investors own 68.16% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of ARS Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, June 28th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $31.00.

Insider Buying and Selling

In other ARS Pharmaceuticals news, Director Brent L. Saunders sold 120,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $14.25, for a total value of $1,710,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder James E. Flynn sold 740,149 shares of the stock in a transaction that occurred on Friday, June 27th. The shares were sold at an average price of $18.46, for a total value of $13,663,150.54. Following the completion of the sale, the insider directly owned 4,887,254 shares of the company's stock, valued at approximately $90,218,708.84. This represents a 13.15% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,043,118 shares of company stock valued at $18,024,863 in the last ninety days. Company insiders own 33.50% of the company's stock.

ARS Pharmaceuticals Stock Down 1.5%

Shares of SPRY stock traded down $0.26 during trading hours on Tuesday, reaching $17.59. 748,375 shares of the company's stock were exchanged, compared to its average volume of 1,361,028. The company has a current ratio of 11.00, a quick ratio of 10.74 and a debt-to-equity ratio of 0.30. The company has a market cap of $1.73 billion, a price-to-earnings ratio of -109.93 and a beta of 0.90. The stock's 50 day moving average is $15.61 and its 200-day moving average is $13.68. ARS Pharmaceuticals, Inc. has a fifty-two week low of $8.91 and a fifty-two week high of $18.90.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, hitting the consensus estimate of ($0.35). ARS Pharmaceuticals had a negative net margin of 16.11% and a negative return on equity of 6.94%. The company had revenue of $7.97 million for the quarter, compared to the consensus estimate of $7.48 million. Analysts predict that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current fiscal year.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.